Innovation | Novartis United States of America

Media Release
Sep 12, 2018
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis
Media Release
Oct 27, 2018
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
Media Release
Oct 22, 2018
Novartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis
Media Release
Oct 09, 2018
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Media Release
Nov 11, 2018
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Media Release
Nov 02, 2018
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Media Release
Oct 29, 2018
Novartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
Media Release
Dec 01, 2018
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
Media Release
Nov 16, 2018
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Media Release
Nov 14, 2018
Novartis to fund five innovative ideas to support patients and the sickle cell community
Media Release
Dec 06, 2018
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
Media Release
Dec 02, 2018
Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies